Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    34.249,77
    +310,02 (+0,91%)
     

  • Dow Jones

    38.286,29
    +200,49 (+0,53%)
     

  • Nasdaq

    15.953,87
    +342,11 (+2,19%)
     

  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     

  • Petrolio

    83,62
    +0,05 (+0,06%)
     

  • Bitcoin EUR

    59.687,73
    -683,53 (-1,13%)
     

  • CMC Crypto 200

    1.331,04
    -65,50 (-4,69%)
     

  • Oro

    2.349,00
    +6,50 (+0,28%)
     

  • EUR/USD

    1,0702
    -0,0031 (-0,29%)
     

  • S&P 500

    5.107,93
    +59,51 (+1,18%)
     

  • HANG SENG

    17.651,15
    +366,61 (+2,12%)
     

  • Euro Stoxx 50

    5.006,85
    +67,84 (+1,37%)
     

  • EUR/GBP

    0,8564
    -0,0010 (-0,12%)
     

  • EUR/CHF

    0,9777
    -0,0008 (-0,08%)
     

  • EUR/CAD

    1,4617
    -0,0032 (-0,22%)
     

TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

TG Therapeutics, Inc.
·1 minuto per la lettura
TG Therapeutics, Inc.
TG Therapeutics, Inc.

Fireside chat available for on demand download beginning Monday, September 12 2022 at 7:00 AM ET

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate virtually in a fireside chat at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022.

A webcast of the fireside chat will be available for on demand download beginning on Monday, September 12, 2022, at 7:00 AM ET on the conference website. The webcast will also be available on TG’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6